Catalog No.
VMF64002
Species reactivity
Mouse
Host species
Mouse
Isotype
lgG1 (D265A)
Clonality
Monoclonal
Target
Tyrosine-protein phosphatase non-receptor type substrate 1, SHP substrate 1, SHPS-1, Brain Ig-like molecule with tyrosine-based activation motifs, Bit, CD172 antigen-like family member A, Inhibitory receptor SHPS-1, MyD-1 antigen, Signal-regulatory protein alpha-1, Sirp-alpha-1, mSIRP-alpha1, p84, CD172a, Sirpa, Bit, Myd1, Ptpns1, Shps1, Sirp
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P97797
Applications
ELISA, Neutralization
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
Iv0259
A human antibody specific for SIRPα reprograms macrophages and promotes antibody mediated anti-cancer activity., PMID:40408355
Targeted CD47 checkpoint blockade using a mesothelin-directed antibody construct for enhanced solid tumor-specific immunotherapy., PMID:40402266
Dual targeting of ENPP3 and SIRPα with a bispecific antibody enhances macrophage-mediated immunity in renal cell carcinoma., PMID:40349459
Refolding of the recombinant IgV domain of CD47 from E. coli for NMR studies., PMID:40334763
A proteogenomic tool uncovers protein markers for human microglial states., PMID:40236015
Maplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacy., PMID:40078999
Expression of SIRPα-Fc by oncolytic virus enhances antitumor efficacy through tumor microenvironment reprogramming., PMID:40070841
MicroRNA-induced reprogramming of tumor-associated macrophages for modulation of tumor immune microenvironment., PMID:40024340
The clinical significance of signal regulatory protein alpha expression in the immune environment of gastric cancer., PMID:39589589
Preclinical pharmacology characterization of HX009, a novel PD1 x CD47 Bi-specific antibody., PMID:39548213
Silencing of SIRPα enhances the antitumor efficacy of CAR-M in solid tumors., PMID:39379603
Development of bioassay platforms for biopharmaceuticals using Jurkat-CAR cells by AICD., PMID:39197208
Deciphering the role of CD47 in cancer immunotherapy., PMID:39167629
Efficient generation of human immune system rats using human CD34+ cells., PMID:39151431
A polymeric nanoplatform enhances the cGAS-STING pathway in macrophages to potentiate phagocytosis for cancer immunotherapy., PMID:39038546
CD47-SIRPα Blockade Sensitizes Head and Neck Squamous Cell Carcinoma to Cetuximab by Enhancing Macrophage Adhesion to Cancer Cells., PMID:38959336
Blockade of the CD47/SIRPα checkpoint axis potentiates the macrophage-mediated antitumor efficacy of tafasitamab., PMID:38934068
A Perspective on the CD47-SIRPA Axis in High-Risk Neuroblastoma., PMID:38920727
Engineering nanoparticles-enabled tumor-associated macrophages repolarization and phagocytosis restoration for enhanced cancer immunotherapy., PMID:38890636
Blockade of SIRPα-CD47 axis by anti-SIRPα antibody enhances anti-tumor activity of DXd antibody-drug conjugates., PMID:38843278
Combining SiRPα decoy-coengineered T cells and antibodies augments macrophage-mediated phagocytosis of tumor cells., PMID:38828721
Engineered CD47 protects T cells for enhanced antitumour immunity., PMID:38750365
Macrophage Checkpoint Nanoimmunotherapy Has the Potential to Reduce Malignant Progression in Bioengineered In Vitro Models of Ovarian Cancer., PMID:38558434
Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction., PMID:38483480
Biomimetic Nano-Degrader Based CD47-SIRPα Immune Checkpoint Inhibition Promotes Macrophage Efferocytosis for Cardiac Repair., PMID:38477522
A Novel Anti-CD47 Nanobody Tetramer for Cancer Therapy., PMID:38247566
Tumor Immune Cell Targeting Chimeras (TICTACs) For Targeted Depletion of Macrophage-Associated Checkpoint Receptors., PMID:38106036
SIRP-alpha-IL-6 axis induces immunosuppressive macrophages in non-small-cell lung cancer., PMID:37844448
SIRPA enhances osteosarcoma metastasis by stabilizing SP1 and promoting SLC7A3-mediated arginine uptake., PMID:37769797
Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1., PMID:37704166
An agonistic anti-signal regulatory protein α antibody for chronic inflammatory diseases., PMID:37490914
Design single-stranded DNA aptamer of cluster of differentiation 47 protein by stochastic tunnelling-basin hopping-discrete molecular dynamics method., PMID:37261868
Characterization and clinical impact of the tumor microenvironment in post-transplant aggressive B-cell lymphomas., PMID:37259566
B7-H3 drives immunosuppression and Co-targeting with CD47 is a new therapeutic strategy in β-catenin activated melanomas., PMID:37086018
Novel Potential Mechanisms of Regulatory B Cell-Mediated Immunosuppression., PMID:37068869
Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction., PMID:36945559
Single-cell atlas of the immune microenvironment reveals macrophage reprogramming and the potential dual macrophage-targeted strategy in multiple myeloma., PMID:36852636
Thrombospondin-1, CD47, and SIRPα display cell-specific molecular signatures in human islets and pancreata., PMID:36791324
Targeting of SIRPα as a potential therapy for Langerhans cell histiocytosis., PMID:36788737
SIRPα-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47/SIRPα signal pathway via blocking the "don't eat me" signal and activating the "eat me" signal., PMID:36384978
Artificial Intelligence Predicted Overall Survival and Classified Mature B-Cell Neoplasms Based on Immuno-Oncology and Immune Checkpoint Panels., PMID:36358737
Revised International Staging System (R-ISS) stage-dependent analysis uncovers oncogenes and potential immunotherapeutic targets in multiple myeloma (MM)., PMID:36315425
CD47-SIRPα blocking-based immunotherapy: Current and prospective therapeutic strategies., PMID:35908284
CD47-SIRPα Controls ADCC Killing of Primary T Cells by PMN Through a Combination of Trogocytosis and NADPH Oxidase Activation., PMID:35795660
Clinical significance of signal regulatory protein alpha and T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain expression in undifferentiated pleomorphic sarcoma., PMID:35737088
Checkpoint CD47 expression in classical Hodgkin lymphoma., PMID:35301709
DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity., PMID:35287686
Anticancer efficacy of monotherapy with antibodies to SIRPα/SIRPβ1 mediated by induction of antitumorigenic macrophages., PMID:34949714
SIRPγ-CD47 Interaction Positively Regulates the Activation of Human T Cells in Situation of Chronic Stimulation., PMID:34925315
Imaging of Glioblastoma Tumor-Associated Myeloid Cells Using Nanobodies Targeting Signal Regulatory Protein Alpha., PMID:34917090
For research use only. Not for human or drug use.
